Hepatitis B Patients: How to Lower Liver Cancer Risk (as of 2026)

For people living with hepatitis B, the key to lowering risk is staying consistent with antiviral medication and, if cirrhosis is present, catching liver cancer at a small size through ultrasound and blood tests every six months.

Key Takeaways

• Liver cancer usually develops on top of chronic hepatitis or cirrhosis, so for hepatitis B carriers, lifelong antiviral treatment and liver function testing are the basic foundation.
• Korea runs a national screening program offering ultrasound and blood tests every six months for hepatitis B carriers and cirrhosis patients, which tends to result in a relatively high rate of detecting cancer at a small size.
• Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea, Central Cancer Registry), and this is a nationwide statistic, not the outcome of any particular hospital.
• Abstaining from alcohol is recommended both during and after liver cancer treatment, since protecting the remaining liver function widens the range of treatment options available later.
• The National Cancer Prevention Guidelines include hepatitis B vaccination, a balanced diet, smoking cessation, avoiding alcohol even in small amounts, maintaining a healthy weight, and regular screening (National Cancer Information Center).

Why Are Hepatitis B Carriers at Higher Risk of Liver Cancer?

• Unlike many other cancers, liver cancer often develops on top of an underlying condition such as chronic hepatitis or cirrhosis. This means that alongside cancer stage, liver function grade (Child-Pugh) and portal pressure also strongly shape the treatment direction.
• For this reason, hepatitis B carriers benefit not only from preventing liver cancer itself but also from preserving liver function over the long term, since doing so widens the range of treatment options available later. Even for tumors of the same size, the treatments that can be used differ depending on liver function.
• As a rule, antiviral medication should be continued without interruption before and after liver cancer treatment — a management principle that applies to hepatitis B carriers in general.

Why Does Screening Every 6 Months Matter?

• Korea operates a national screening system that provides ultrasound and blood tests every six months for hepatitis B carriers and cirrhosis patients, which contributes to a relatively high rate of detecting liver cancer while it is still small.
• Early detection increases the chance that curative treatments such as liver resection, radiofrequency ablation, or liver transplantation can be considered. In contrast, if the tumor is found after invading blood vessels or spreading outside the liver, the approach shifts toward systemic drug therapy as the main treatment.
• Testing includes ultrasound along with tumor markers such as AFP and liver function tests (bilirubin, albumin, coagulation values); reviewing imaging together with liver function results is central to accurate interpretation.

How Can Lifestyle Management Help Protect the Liver?

• The National Cancer Prevention Guidelines include avoiding tobacco and secondhand smoke, eating a balanced diet with plenty of vegetables and fruit, avoiding salty and charred foods, avoiding alcohol even in small amounts for cancer prevention, exercising to the point of sweating for at least 30 minutes a day on 5 or more days a week, maintaining a healthy weight, getting vaccinated against hepatitis B and cervical cancer, and undergoing regular screening (National Cancer Information Center).
• Alcohol is reported to potentially raise the risk of recurrence or secondary cancers, and people who do not currently drink are not advised to start drinking for any reason (U.S. National Cancer Institute, NCI). For hepatitis B carriers, abstaining from alcohol carries particular significance.
• There is evidence that continuing to smoke after diagnosis is associated with increased risk of recurrence or secondary cancers and reduced treatment response, making smoking cessation a fundamental part of managing liver cancer risk.

If Liver Cancer Is Already Found, What Is the Treatment Pathway?

• Step 1: Contrast-enhanced CT or MRI is used to check for the blood flow pattern characteristic of liver cancer, along with tumor markers such as AFP. A biopsy is added only when imaging findings are ambiguous or metastasis is suspected.
• Step 2: Staging considers three factors together — the number, size, and vascular invasion of tumors; liver function (Child-Pugh); and overall physical condition.
• Step 3: For very early or early stages, liver resection or radiofrequency ablation is considered; if liver function has declined significantly but the patient meets the criteria, liver transplantation may be considered.
• Step 4: For intermediate stage with multiple tumors within the liver, transarterial chemoembolization is the main approach; for advanced stage with vascular invasion or spread outside the liver, systemic drug therapy combining immune checkpoint inhibitors with angiogenesis inhibitors is part of the standard treatment.
• Step 5: After treatment, contrast-enhanced CT or MRI and AFP testing are repeated every few months for the first 1–2 years, while hepatitis B antiviral treatment and liver function testing continue for life.

FAQ — Do I need to keep taking hepatitis B medication?

Yes, as a rule, antiviral medication should be continued without interruption before and after liver cancer treatment. Since hepatitis B is one of the main underlying conditions behind liver cancer, maintaining viral suppression — regardless of whether treatment is underway — helps preserve liver function and manage recurrence risk.

FAQ — Whose results do the survival rate figures represent?

They represent nationwide statistics for Korea as a whole, not the results of any particular hospital. The 5-year relative survival rate of 40.4% for liver cancer is based on National Cancer Registration Statistics 2019–2023 (National Cancer Center Korea, Central Cancer Registry); for reference, the U.S. SEER 2016–2022 data show a 5-year relative survival rate of 21.9% for liver and intrahepatic bile duct cancer. Both figures are population averages and are not predictive of any individual's outcome.

Sources and Notes

• This article was written based on the Liver Cancer Note (National Cancer Registration Statistics 2019–2023 · National Cancer Center Korea, SEER, NCCN Patient Guidelines) and the Cancer Survivor Health Management Note (National Cancer Information Center, U.S. National Cancer Institute, NCI).
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult with a medical professional to determine accurate diagnosis and treatment.